Pathologic Changes Related to CMF Primary Chemotherapy in Breast Cancer

By Moreno A.   Escobedo A.   Benito E.   Serra J.M.   Gumà A.   Riu F.  

Breast Cancer Research and Treatment, Vol. 75, Iss. 2, 2002-09 ,pp. : 119-125

Springer Publishing Company

Access to resources Recommend Favorite

Prediction of response to primary chemotherapy for operable breast cancer

By Colleoni M.   Orvieto E.   Nole   Orlando L.   Minchella I.   Viale G.   Peruzzotti G.   Robertson C.   Noberasco C.   Galimberti V.   Sacchini V.   Veronesi P.   Zurrida S.   Orecchia R.   Goldhirsch A.  

European Journal of Cancer, Vol. 35, Iss. 4, 1999-04 ,pp. : 574-579

Elsevier

Access to resources Recommend Favorite

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 3, 2004-09 ,pp. : 211-213

Informa Healthcare

Access to resources Recommend Favorite

Preoperative Therapy Using Trastuzumab and Weekly Paclitaxel in a Stage III B Inoperable Locally Advanced HER2-Positive Breast Cancer with Complete Pathologic Response

By Rai Yoshiaki   Sagara Yoshiatsu   Ooi Yasuyo   Yasuaki   Sagara Yoshiaki   Baba Shinichi   Tamada Syugo   Matsuyama Yoshito   Ando Mitsutake  

Japanese Journal of Cancer and Chemotherapy, Vol. 36, Iss. 3, 2009-03 ,pp. : 471-473

Sunmedia

Access to resources Recommend Favorite

Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer

By Wist Erik Andreas   Sommer Hilde Heen   Østenstad Bjørn   Risberg Terje   Fjæstad Knut  

Acta Oncologica, Vol. 43, Iss. 1, 2004-03 ,pp. : 11-14

Informa Healthcare

Access to resources Recommend Favorite